Prieto 2006.
Methods | Randomised, double‐blind, parallel‐group, placebo‐controlled trial | |
Participants | N = 34. Mean age unclear. Treatment group: 18; control group: 16 Inclusion criteria: mild to moderate allergic asthma |
|
Interventions | Subcutaneous omalizumab versus placebo (dosage unclear) Treatment lasted for 12 weeks |
|
Outcomes | Airway responsiveness | |
Notes | Unpublished conference abstract: Jadad score: 2 | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Details of sequence generation not included in trial report |
Allocation concealment (selection bias) | Unclear risk | Details of allocation concealment not included in trial report |
Blinding (performance bias and detection bias) All outcomes | Low risk | Double‐blind |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Five participants did not complete the trial, and reasons for withdrawal are included in the trial report |
Selective reporting (reporting bias) | Unclear risk | No apparent indication of selective reporting bias |